Revolution Medicines, Inc. $RVMD Shares Purchased by S&CO Inc.

S&CO Inc. grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 56.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,171 shares of the company’s stock after buying an additional 8,000 shares during the quarter. S&CO Inc.’s holdings in Revolution Medicines were worth $1,035,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. GAMMA Investing LLC boosted its position in Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the period. California State Teachers Retirement System lifted its stake in shares of Revolution Medicines by 0.3% during the second quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock worth $5,153,000 after purchasing an additional 437 shares in the last quarter. CWM LLC boosted its position in shares of Revolution Medicines by 171.3% in the second quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after buying an additional 579 shares during the period. Arizona State Retirement System grew its stake in shares of Revolution Medicines by 1.6% in the third quarter. Arizona State Retirement System now owns 41,299 shares of the company’s stock valued at $1,929,000 after buying an additional 646 shares in the last quarter. Finally, Avanza Fonder AB grew its stake in shares of Revolution Medicines by 17.5% in the third quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock valued at $202,000 after buying an additional 647 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Stifel Nicolaus started coverage on Revolution Medicines in a report on Wednesday, October 15th. They issued a “buy” rating and a $85.00 price target for the company. Raymond James Financial boosted their target price on shares of Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a research report on Friday, October 17th. Wolfe Research initiated coverage on shares of Revolution Medicines in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 target price for the company. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, Mizuho began coverage on shares of Revolution Medicines in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 price objective for the company. Four research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $78.94.

Insider Transactions at Revolution Medicines

In other news, COO Margaret A. Horn sold 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $100.56, for a total value of $7,542,000.00. Following the completion of the sale, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. The trade was a 34.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen Michael Kelsey sold 5,447 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $418,438.54. Following the sale, the insider directly owned 278,600 shares in the company, valued at approximately $21,402,052. This represents a 1.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 213,792 shares of company stock valued at $17,948,440 over the last ninety days. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines Trading Down 0.8%

NASDAQ RVMD opened at $96.74 on Tuesday. The company has a market capitalization of $18.70 billion, a price-to-earnings ratio of -18.71 and a beta of 1.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $124.49. The company’s fifty day moving average price is $92.93 and its two-hundred day moving average price is $64.55.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.